Guillain-Barre syndrome: background incidence rates in The Netherlands

被引:14
|
作者
van der Maas, Nicoline A. T. [1 ,2 ,3 ]
Kramer, Merlijn A. [1 ]
Jacobs, Bart C. [2 ,3 ]
van Soest, Eva M. [4 ]
Dieleman, Jeanne P. [4 ]
Kemmeren, Jeanet M. [1 ]
de Melker, Hester E. [1 ]
Sturkenboom, Miriam C. J. M. [5 ]
机构
[1] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands
[2] Univ Med Ctr, Dept Neurol, Rotterdam, Netherlands
[3] Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands
[4] Univ Med Ctr, Dept Med Informat, Rotterdam, Netherlands
[5] Univ Med Ctr, Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands
关键词
Guillain-Barre syndrome; incidence rate; vaccination; PATIENT RECORDS; IMMUNIZATION; SURVEILLANCE; FEATURES;
D O I
10.1111/j.1529-8027.2011.00356.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Guillain-Barre syndrome (GBS) is a (sub) acute polyradiculoneuropathy, which may occur following immunization. To interpret the occurrence of GBS after introduction of large-scale immunization programmes, it is important to define recent background incidence rates (IRs) of GBS. We used a general practitioner electronic medical record database to assess age-specific GBS IRs between 1996 and 2008 in The Netherlands. All possible GBS cases were manually reviewed. Validated incident cases were reviewed by a neurologist (B. J.) for diagnostic certainty using the GBS case definition of the Brighton Collaboration (BC). In a population of 638,891 persons, we identified 23 validated incident GBS cases (mean age 46 years). IR was 1.14 per 100,000 person years (95% confidence interval [CI] 0.67-1.61) and was lower for people under 50 years (0.76; 95% CI 0.41-1.32) compared with elderly of 50 years or older (1.80; 95% CI 0.98-3.05). Only six cases fulfilled level 1 or 2 of diagnostic certainty of the BC case definition. IR of GBS increases with age. As vaccinations are often targeted at specific age groups, age-specific rates should be used to monitor GBS observed versus expected rates after introduction of large-scale vaccination programmes.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 50 条
  • [11] Guillain-Barre syndrome
    Wakerley, Benjamin R.
    Yuki, Nobuhiro
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (08) : 847 - 849
  • [12] Guillain-Barre syndrome
    Seneviratne, U
    POSTGRADUATE MEDICAL JOURNAL, 2000, 76 (902) : 774 - 782
  • [13] Guillain-Barre syndrome
    Esposito, Susanna
    Longo, Maria Roberta
    AUTOIMMUNITY REVIEWS, 2017, 16 (01) : 96 - 101
  • [14] Guillain-Barre Syndrome
    Pasanen, Mark E.
    HOSPITAL MEDICINE CLINICS, 2015, 4 (02) : 177 - 190
  • [15] Guillain-Barre Syndrome
    Kaida, Kenichi
    MYELIN: BASIC AND CLINICAL ADVANCES, 2019, 1190 : 323 - 331
  • [16] Guillain-Barre Syndrome
    Arcila-Londono, Ximena
    Lewis, Richard A.
    SEMINARS IN NEUROLOGY, 2012, 32 (03) : 179 - 186
  • [17] Mild forms of Guillain-Barre syndrome in an epidemiologic survey in the Netherlands
    Van Koningsveld, R
    Van Doorn, PA
    Schmitz, PIM
    Ang, CW
    Van der Meché, FGA
    NEUROLOGY, 2000, 54 (03) : 620 - 625
  • [18] Guillain-Barre syndrome and influenza vaccines: current evidence
    Sanz Fadrique, Rosario
    Arias, Luis Martin
    Arcadio Molina-Guarneros, Juan
    Jimeno Bulnes, Natalia
    Garcia Ortega, Pilar
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2019, 32 (04) : 288 - 295
  • [19] Guillain-Barre syndrome following hepatitis B vaccination
    Khamaisi, M
    Shoenfeld, Y
    Orbach, H
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (06) : 767 - 770
  • [20] Therapy of Guillain-Barre syndrome
    Zagar, M
    Vranjes, D
    Bilic, E
    Mitrovic, Z
    Jurenic, D
    Sostarko, M
    Voglein, S
    NEUROLOGIA CROATICA, 2005, 54 (1-2): : 19 - 26